Advances in the research and application of stem cell therapies for idiopathic pulmonary fibrosis.
Xu L., Hou X., Zhou X., Jiang M.
Clinical Trial on Scar, Chronic Inflammation, published in Am J Clin Exp Immunol (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Am J Clin Exp Immunol (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41567723
- PMCID
- PMC12816817
- DOI
- 10.62347/GLJG9463
Abstract (original English)
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease primarily affecting the elderly, marked by lung tissue scarring and impaired function. Current treatments, such as pirfenidone and nintedanib, slow disease progression but do not halt it and are associated with side effects. Lung transplantation is limited by donor shortages and surgical risks. Stem cell-based therapies, particularly mesenchymal stromal cells (MSCs) from bone marrow, adipose tissue, and umbilical cord, offer promise due to their low immunogenicity, homing capacity, and paracrine signaling. Preclinical models show that MSCs or their miRNA-bearing extracellular vehicles (EVs) can inhibit the TGFβ/Smad pathway, reprogram macrophage polarization, and promote tissue regeneration through anti-inflammatory and repair factors (e.g., IL-10, HGF, VEGF). Genetic modifications like CXCR4 overexpression may enhance MSC efficacy. Early clinical trials suggest favorable safety and preliminary efficacy, though long-term validation is needed. Additionally, alveolar type 2 (AT2) cells derived from induced pluripotent stem cells (iPSCs) and lung epithelial cells from embryonic stem cells (ESCs) offer potential for alveolar repair. Bioengineering advancements, including hydrogel scaffolds and 3D lung organoids, enhance stem cell retention and provide platforms for IPF research and drug screening. This review
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations